Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme
OBJECTIVES: I. Assess the toxicity of suramin administered prior to and concurrent with
radiotherapy in patients with newly diagnosed high grade glioblastoma multiforme. II.
Evaluate this regimen in terms of survival in this patient population.
OUTLINE: Patients receive suramin IV over 2 hours for initial dose and over 1 hour for
subsequent doses daily for 5 days on week 1. Patients receive concurrent radiotherapy daily
with suramin IV over 1 hour twice weekly on weeks 2-7. Patients with stable or responsive
disease receive a second course of suramin twice weekly on weeks 20-24. Treatment continues
in the absence of disease progression or unacceptable toxicity. Patients are followed every
2 months until disease progression or start of new therapy and then monthly for survival.
PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study over 1.5 years.
Primary Purpose: Treatment
John J. Laterra, MD, PhD
Sidney Kimmel Comprehensive Cancer Center
United States: Food and Drug Administration
|University of Alabama Comprehensive Cancer Center||Birmingham, Alabama 35294|
|H. Lee Moffitt Cancer Center and Research Institute||Tampa, Florida 33612|
|Emory University Hospital - Atlanta||Atlanta, Georgia 30322|
|Johns Hopkins Oncology Center||Baltimore, Maryland 21287|
|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center||Winston-Salem, North Carolina 27157-1082|
|University of Pennsylvania Cancer Center||Philadelphia, Pennsylvania 19104|
|University of Texas Health Science Center at San Antonio||San Antonio, Texas 78284-7811|
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Henry Ford Hospital||Detroit, Michigan 48202|